NMN and NR Manufacturing, Supply, and Shortage History: What Women Need to Know

What NMN and NR Are, and Why Manufacturing Matters for Women

NMN and NR are two distinct molecules that your body converts into NAD+ (nicotinamide adenine dinucleotide), a coenzyme that declines with age and is central to energy metabolism, DNA repair, and mitochondrial function. The specific pathway each molecule takes differs, and those differences affect bioavailability, pricing, and the supply chain.

For women, NAD+ biology is not neutral. Estrogen receptors interact with sirtuins, the NAD+-dependent enzymes that regulate gene expression and cellular stress responses, and NAD+ levels drop sharply during the menopause transition, potentially amplifying metabolic and cardiovascular risk. That hormonal context is exactly why understanding who makes these supplements, where, and under what regulatory oversight matters more than it might for a generic vitamin.

How NMN Is Synthesized

NMN is synthesized commercially through two main routes. The enzymatic route uses a nicotinamide phosphoribosyltransferase (NAMPT) enzyme system to convert nicotinamide and 5-phosphoribosyl-1-pyrophosphate (PRPP) into NMN. The chemical route uses a series of organic reactions starting from ribose. Both produce a white crystalline powder with a molecular weight of 334.22 g/mol.

The enzymatic route yields a higher-purity product but requires controlled bioreactor conditions, skilled fermentation technicians, and cold-chain transport to preserve enzyme activity. That complexity concentrates production in a small number of GMP-certified facilities.

How NR Is Synthesized

NR (nicotinamide riboside) is synthesized primarily through chemical glycosylation reactions that attach nicotinamide to a ribose sugar. Chromadex, a California-based company, holds key patents on NR production under the brand name Tru Niagen and supplies most of the NR used in branded supplements worldwide. This patent concentration means the NR supply chain has a single point of origin in ways the NMN chain does not, creating different risk profiles for shortage.

NR enters cells via specific nucleoside transporters and is phosphorylated intracellularly to NMN before conversion to NAD+. NMN, by contrast, may be converted to NR extracellularly before cell entry, or may enter cells via the Slc12a8 transporter, though the relative importance of each route in humans remains under active study.

The Global Manufacturing Field Before 2021

Before the FDA's 2022 enforcement letter reshaped the U.S. Market, the global NMN supply chain was expanding rapidly. Demand surged after David Sinclair's 2013 research at Harvard (published in Cell) demonstrated that NAD+ repletion reversed aspects of vascular aging in mice. That mouse data drove consumer demand years before adequate human trials existed, a pattern that would later create regulatory pressure.

China's Dominance in NMN Production

By 2019, more than 90% of the bulk NMN powder sold globally originated from manufacturers in China, principally in Zhejiang, Jiangsu, and Guangdong provinces. Companies such as Bontac Bio-Engineering (Shenzhen) and Herzo Materials Science became major exporters. Bontac claims an enzymatic fermentation process certified to ISO 9001 and claims output capacity exceeding 20 metric tons of NMN per year, though independent verification of those figures is not publicly available.

Chinese manufacturers competed primarily on price, and bulk NMN powder dropped from roughly $5,000 per kilogram in 2018 to under $500 per kilogram by 2021. That price collapse democratized access but also raised quality-control concerns. Third-party testing by ConsumerLab.com in 2021 found that several NMN supplements contained less than the labeled dose of NMN, with one product containing only 0% of its claimed NMN content.

Japan's Role in Quality-Tier Manufacturing

Japanese manufacturers, including Mitsubishi Gas Chemical's subsidiary Oriental Yeast Co. And GeneHarbor Biotechnologies, positioned themselves in the premium segment by emphasizing third-party purity testing and GMP compliance under Japan's stricter pharmaceutical manufacturing standards. Japanese NMN typically commanded a 3- to 5-fold price premium over Chinese equivalents but offered better documented purity certificates of analysis.

South Korea added manufacturing capacity between 2019 and 2021, primarily for the domestic Korean supplement market, which has a strong functional-food culture.

NR's Concentrated Supply Chain

Chromadex's patent portfolio on NR, particularly patents surrounding the Tru Niagen crystalline form, meant that any company selling NR in the United States was legally licensing that ingredient from Chromadex or risking infringement. A 2016 lawsuit between Chromadex and Elysium Health (which marketed Basis, an NR-containing supplement) dragged through U.S. Courts until 2021 and created significant uncertainty for brands that wanted to stock NR independently. Elysium alleged Chromadex engaged in anticompetitive behavior; the litigation ultimately settled. The legal dispute did not cause physical shortages but did suppress market competition and likely elevated retail NR prices throughout that period.

The 2021 to 2022 Inflection Point: FDA Enforcement and Market Disruption

The most significant event in NMN supply history was not a manufacturing failure. It was a regulatory determination.

The FDA Exclusion Ruling for NMN

In November 2022, the FDA responded to a citizen petition filed in 2021 by Metro International Biotech, a Massachusetts company that was developing an NMN-based pharmaceutical (known as MIB-626). The FDA concluded that because NMN had been authorized for investigation as a new drug before it was marketed as a dietary supplement, it could not lawfully be sold as a dietary supplement under 21 U.S.C. 321(ff)(3)(B). The FDA's citizen petition response is publicly available and explicitly states: "FDA has concluded that NMN is excluded from the dietary supplement definition."

This was not a safety action. The FDA did not declare NMN dangerous. But the ruling created immediate market disruption. Major U.S. Retailers including Amazon pulled NMN products from their platforms in early 2023, causing shortages at consumer level even though the bulk manufacturing supply chain was fully functional. Women who had been using NMN for metabolic support, particularly after seeing the Yoshino et al. 2021 data, found products disappearing from shelves overnight.

The Yoshino Trial and Why Women Were Already Paying Attention

The Yoshino et al. Study published in Science in 2021 was the first randomized, placebo-controlled trial of NMN specifically in postmenopausal women. Yoshino et al. Enrolled 25 overweight or obese postmenopausal women with prediabetes and randomized them to 250 mg/day of oral NMN or placebo for 10 weeks. NMN supplementation improved skeletal muscle insulin signaling, increased expression of genes involved in muscle remodeling, and raised whole-blood NAD+ metabolite levels. No significant adverse events were reported.

This trial matters for the supply story because it was the first human evidence targeted at women in a life stage (postmenopausal) where NAD+ decline is most clinically relevant. It created a specific demographic of informed women seeking NMN precisely when regulatory disruption was making it harder to obtain. That demand-supply mismatch drove a surge in gray-market NMN sourcing, with women buying directly from Chinese bulk suppliers or through international retailers, bypassing the quality controls that U.S.-based brands had provided.

Amazon's Removal and the Ripple Effect

Amazon's decision to delist NMN products in January 2023 following the FDA advisory affected more than 300 active product listings according to industry tracking by Nutrition Business Journal. The removal was not legally required under the FDA advisory, which was a guidance position rather than a mandatory recall, but Amazon applied a conservative interpretation. The delisting lasted approximately 6 months before Amazon quietly re-allowed NMN listings, citing ongoing regulatory ambiguity.

During that window, NMN prices on remaining available platforms spiked by 40 to 60% according to price tracking data from Stackline, a retail analytics firm. Women in perimenopause and postmenopause, the demographic most actively using NMN based on the scientific rationale, bore disproportionate cost burden.

What Happened to Supply Quality During the Shortage

Supply disruptions rarely improve quality. The 2022 to 2023 disruption was no exception.

Third-Party Testing Failures

When branded U.S. Products disappeared from Amazon, consumers turned to unfamiliar brands with no established testing records. A 2022 analysis by Labdoor found significant label inaccuracy across the NMN supplement category, with some products delivering as little as 5% of stated NMN content. During shortage periods, adulteration with cheaper nicotinamide (plain niacinamide, which is not an NAD+ precursor via the same pathway) was reported by multiple contract labs.

Nicotinamide itself is not harmful. But substituting it for NMN defeats the purpose of supplementation. A woman taking 250 mg/day of a product labeled as NMN but actually containing nicotinamide is not replicating the Yoshino et al. Protocol.

Cold-Chain and Stability Concerns

NMN degrades when exposed to heat and moisture. The enzymatic-route NMN from Japanese manufacturers is typically packaged under nitrogen with moisture-absorbing desiccants and shipped cold. Bulk Chinese NMN, particularly product moving through informal resale channels during the shortage, was frequently shipped at ambient temperature with inadequate packaging. NMN stability studies show <5% degradation over 24 months at 25°C when properly packaged, but that figure does not apply to product stored improperly.

NR Supply Stability by Comparison

Because NR supply runs through Chromadex's controlled manufacturing and licensing network, NR did not experience the same market disruption as NMN during 2022 to 2023. NR remained available on Amazon throughout the period. Women who switched from NMN to NR during that window made a pragmatic but scientifically distinct substitution: NR has its own evidence base, including a 2018 trial by Dollerup et al. In the Nature Communications showing NAD+ augmentation in healthy men, but the specific postmenopausal-women metabolic data from Yoshino et al. Used NMN, not NR.

Current Regulatory Status and What It Means for Women Buying These Products

The FDA has not issued a mandatory recall of NMN. The agency's position is that NMN cannot be lawfully marketed as a dietary supplement, but enforcement against individual products has been minimal and inconsistent. NMN products are again widely available online as of 2025.

The practical result is a market where:

• Products labeled as NMN may or may not contain what they claim
• No FDA pre-market review has occurred for any NMN supplement
• GMP compliance is self-declared by most manufacturers
• Certificate of analysis quality varies enormously between suppliers

NR remains in a cleaner regulatory position. Chromadex submitted a New Dietary Ingredient Notification (NDIN) for NR in 2015, and the FDA acknowledged the notification without objection, meaning NR has a documented regulatory pathway as a dietary supplement ingredient.

Pregnancy, Lactation, and Contraception: A Required Assessment

NMN and NR are not recommended during pregnancy or lactation. This is not a reflexive precaution. It reflects a genuine absence of human safety data in these populations.

NAD+ is essential for embryonic development. Animal studies show that NAD+ deficiency during pregnancy causes congenital malformations, particularly affecting the heart, kidneys, and vertebrae. This was established by Shi et al. In the New England Journal of Medicine in 2017, who identified that NAD+ precursor deficiency in mice causes multi-organ birth defects. The implication is that adequate NAD+ is necessary, but the question of whether supraphysiologic supplementation is safe or beneficial in human pregnancy has not been studied.

No randomized trials of NMN or NR have included pregnant women. No lactation transfer data for NMN or NR exists in peer-reviewed literature. Because NAD+ metabolites are biologically active and small enough to cross the placenta and enter breast milk, caution is the only defensible clinical stance.

If you are trying to conceive, currently pregnant, or breastfeeding, stop NMN or NR and speak with your OB-GYN or midwife. These supplements do not require a washout period given their short half-life, but their use during pregnancy is not supported by any evidence.

There is no contraceptive requirement tied to NMN or NR use. Neither molecule is known to be teratogenic at studied doses. The recommendation to avoid use in pregnancy is precautionary, not because harm has been demonstrated, but because safety has not been established.

Who This Is Most Relevant For, and Who Should Be Cautious

Women Who May Have the Strongest Rationale for Use

The only randomized controlled trial in women studied postmenopausal women with prediabetes or overweight. If you fall into that category, the Yoshino et al. Data at 250 mg/day of NMN is the closest thing to evidence-based dosing available. The trial showed statistically significant improvement in skeletal muscle insulin signaling without serious adverse events over 10 weeks.

Women in perimenopause experiencing metabolic changes, particularly rising fasting glucose, increasing insulin resistance, or shifting body composition, represent a population where the NAD+-estrogen interaction may be clinically meaningful, though direct trial data in perimenopausal women specifically is lacking.

Women Who Should Exercise Caution or Avoid Use

• Pregnant or breastfeeding women (see section above)
• Women with a personal or family history of hormone-sensitive cancers: NAD+ supports DNA repair but also cellular proliferation; the net effect in hormone-sensitive tissue has not been studied adequately in women
• Women taking medications that interact with NAD+ metabolism, including isoniazid (used in tuberculosis treatment) or certain chemotherapy agents
• Women with chronic kidney disease, where metabolite clearance may differ from the studied population

The evidence gap in women is substantial. Outside of Yoshino et al. And a small number of open-label studies, randomized trial data in women across any life stage is thin. This is consistent with the broader pattern of women being underrepresented in metabolic and longevity research.

How to Evaluate NMN and NR Products Given the Supply Chain History

Given the manufacturing concentration, quality variability, and regulatory ambiguity described above, here is a concrete framework for product evaluation:

Certificate of Analysis (CoA): Ask for or find the manufacturer's CoA showing NMN or NR purity by HPLC. Purity should be 98% or higher. The CoA should include a batch number that matches your product lot.

Third-party testing: Look for products tested by NSF International, USP, or Informed Sport. These are independent verification programs. A product tested by a named third-party lab is meaningfully different from one that claims "GMP certified" without a verifiable certificate.

Manufacturer country and facility: Japanese and Swiss manufacturers generally have stricter regulatory oversight than Chinese manufacturers, though excellent Chinese manufacturers exist. Ask the brand specifically which facility produces their bulk NMN or NR.

Stability packaging: NMN in a clear plastic bottle with no desiccant is a red flag. Look for amber or opaque packaging with nitrogen flushing or desiccant packs.

Price as a signal: Bulk NMN costs roughly $200 to $500 per kilogram wholesale as of 2024. A 30-day supply of 250 mg/day is 7.5 grams of NMN. Raw material cost is therefore $1.50 to $3.75 for the NMN itself. Products priced below $20 for a month's supply at 250 mg leave almost no margin for quality manufacturing, testing, and encapsulation. Suspiciously low prices warrant scrutiny.

If you switch from NMN to NR during any future supply disruption, use products that explicitly state they contain Tru Niagen (Chromadex-licensed NR), as this is the form with the most established supply chain integrity and the clearest regulatory status.